Integra LifeSciences posts preliminary Q3 results, updates 2026 guidance

Integra LifeSciences issued unaudited Q3 2026 prelims of $410M—$412M revenue and $0.55—$0.59 EPS, and cut FY26 guidance to $1.634B—$1.654B revenue and $2.30—$2.40 EPS, citing July flooding impacts. It expects $190M—$200M operating cash flow in 2026.Material DetailsContext by AI AnalystThis is a mid…